2023
Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature
Mogica J, Tang H, Liang Y, Zhong M, Hui P, Harigopal M, Krishnamurti U, Fischbach N, Zhan H. Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature. The Breast 2023, 72: 103586. PMID: 37812963, PMCID: PMC10568274, DOI: 10.1016/j.breast.2023.103586.Peer-Reviewed Original ResearchConceptsHER2 IHC 3Human epidermal growth factor receptor 2Kaplan-Meier survival analysisHER2-IHC expressionPathologic complete responseResidual diseaseIHC 3Breast cancerIHC expressionSurvival analysisSuperior disease-free survivalEpidermal growth factor receptor 2Intensive adjuvant therapyPost-therapy surveillanceYale Cancer CenterDisease-free survivalGrowth factor receptor 2Recurrence-free survivalSingle institution experienceLow recurrence rateFactor receptor 2HER2 protein expressionAdjuvant trialsNeoadjuvant treatmentAdjuvant therapy
2022
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsTriple-negative breast cancerNon-AA patientsEvent-free survivalPhase I/II clinical trialsClinical trialsNeoadjuvant chemotherapyOverall survivalAA patientsEarly-stage triple-negative breast cancerIncidence of irAEsPathologic complete response rateSignificant associationMultivariate logistic regression analysisTumor-infiltrating lymphocyte countsComplete response ratePrimary efficacy endpointPD-L1 statusProportional hazards modelLogistic regression analysisAfrican American womenEFS ratesNeoadjuvant immunotherapyEfficacy endpointAdverse events
2020
A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancer
Cecchini M, Kortmansky JS, Cui C, Wei W, Thumar JR, Uboha NV, Hafez N, Lacy J, Fischbach NA, Sabbath KD, Gomez CM, Sporn JR, Stein S, Hochster HS. A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer 2020, 127: 1417-1424. PMID: 33351187, PMCID: PMC8085021, DOI: 10.1002/cncr.33379.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsDrug Administration ScheduleDrug CombinationsDrug Resistance, NeoplasmFemaleFluorouracilHumansIrinotecanLeucovorinMaleMiddle AgedOrganoplatinum CompoundsOxaliplatinProgression-Free SurvivalPyrrolidinesResponse Evaluation Criteria in Solid TumorsThymineTrifluridineConceptsMetastatic colorectal cancerOverall response rateRefractory metastatic colorectal cancerProgression-free survivalTAS-102Colorectal cancerDay 1Primary endpointOverall survivalDose escalationDay 5Median progression-free survivalPhase 1b studyMedian overall survivalResponse Evaluation CriteriaTreat populationDose expansionPartial responseStandard dosesUnexpected side effectsStudy treatmentTumor shrinkageUnexpected toxicitiesSide effectsNovel antimetabolite
2018
Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal Of The American Academy Of Dermatology 2018, 79: 1081-1088. PMID: 30025829, DOI: 10.1016/j.jaad.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenDrug EruptionsFemaleHumansLichenoid EruptionsMaleMiddle AgedNeoplasm ProteinsNeoplasmsNivolumabPemphigoid, BullousProgrammed Cell Death 1 ReceptorRetrospective StudiesSkin Diseases, VesiculobullousTertiary Care CentersTreatment OutcomeConceptsPD-L1 therapyAnti-PD-1/PD-L1 therapyBullous disordersBullous eruptionPD-1/PD-L1 therapyCell death ligand-1 therapyAnti-programmed cell death 1Cancer therapyDeath ligand 1 therapySingle tertiary care centerLinear IgA bullous dermatosisYale-New Haven HospitalDistinct therapeutic challengesInterruption of immunotherapyPositive tumor responseSteroid-sparing agentTertiary care centerIgA bullous dermatosisCell death 1New Haven HospitalStable diseaseSystemic corticosteroidsSystemic steroidsMaintenance therapyL1 therapy
2017
Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma
Li J, Yao X, Kortmansky JS, Fischbach NA, Stein S, Deng Y, Zhang Y, Doddamane I, Karimeddini D, Hochster HS, Lacy J. Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma. American Journal Of Clinical Oncology 2017, 40: 146-151. PMID: 25144267, DOI: 10.1097/coc.0000000000000114.Peer-Reviewed Original ResearchConceptsMetastatic gastroesophageal adenocarcinomaProgression-free survivalGastroesophageal adenocarcinomaOverall survivalTreatment-related grade 3/4 toxicityResponse rateMedian progression-free survivalProspective phase II trialLonger progression-free survivalCisplatin-based regimensConfirmed response rateEfficacy of bevacizumabFirst-line bevacizumabOxaliplatin-based regimenUntreated metastatic adenocarcinomaGrade 3/4 toxicitiesMedian overall survivalAddition of bevacizumabPhase II studyPhase II trialModified FOLFOX6GI perforationHemorrhagic eventsII trialII study
2014
Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study
Lynch TJ, Spigel DR, Brahmer J, Fischbach N, Garst J, Jahanzeb M, Kumar P, Vidaver RM, Wozniak AJ, Fish S, Flick ED, Leon L, Hazard SJ, Kosty MP, Investigators O. Safety and Effectiveness of Bevacizumab-Containing Treatment for Non–Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study. Journal Of Thoracic Oncology 2014, 9: 1332-1339. PMID: 25122429, DOI: 10.1097/jto.0000000000000257.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabCarcinoma, Non-Small-Cell LungDisease-Free SurvivalDrug Therapy, CombinationEuropeFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedProspective StudiesSurvival RateTime FactorsTreatment OutcomeUnited StatesVascular Endothelial Growth Factor AConceptsTrial of bevacizumabObservational cohort studyCell lung cancerCohort studyLung cancerARIES observational cohort studyBevacizumab-associated adverse eventsMedian progression-free survivalProspective observational cohort studyReal-world patient populationRecombinant humanized monoclonal antibodyFirst-line bevacizumabProtocol-defined treatmentMedian overall survivalProgression-free survivalEffectiveness of bevacizumabCommunity-based populationHumanized monoclonal antibodyVascular endothelial growth factorEndothelial growth factorSquamous histologyAdvanced NSCLCChemotherapy regimenMetastatic NSCLCAdverse eventsAre Amended Surgical Pathology Reports Getting to the Correct Responsible Care Provider?
Parkash V, Domfeh A, Cohen P, Fischbach N, Pronovost M, Haines GK, Gershkovich P. Are Amended Surgical Pathology Reports Getting to the Correct Responsible Care Provider? American Journal Of Clinical Pathology 2014, 142: 58-63. PMID: 24926086, DOI: 10.1309/ajcpy55evinjclgx.Peer-Reviewed Original ResearchConceptsCare providersTumor board discussionChart reviewPatient chartsPhysician chartsElectronic health record systemsPatient referralMalignant diagnosisErroneous managementSurgical pathologyHealth record systemsClinical teamOriginal diagnosisDiagnostic changesPhysiciansNew physiciansReport reviewPatientsRecord systemReferralDiagnosisEMR systemBoard discussionsDelivery systemReview
2013
Molecular Phenotypes in Triple Negative Breast Cancer from African American Patients Suggest Targets for Therapy
Lindner R, Sullivan C, Offor O, Lezon-Geyda K, Halligan K, Fischbach N, Shah M, Bossuyt V, Schulz V, Tuck DP, Harris LN. Molecular Phenotypes in Triple Negative Breast Cancer from African American Patients Suggest Targets for Therapy. PLOS ONE 2013, 8: e71915. PMID: 24260093, PMCID: PMC3832509, DOI: 10.1371/journal.pone.0071915.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerNegative breast cancerInsulin-like growth factor-1African American patientsAA patientsBreast cancerAmerican patientsAA tumorsHigher breast cancer mortalityLuminal androgen receptorBreast cancer mortalityDistinct transcriptional programsBasal-like subtypeBasal-like phenotypeGrowth factor-1Expression of VEGFHigher tumor vascularizationDrug response profilesEA tumorsRetrospective cohortTNBC patientsEA patientsPoor prognosisTNBC casesTNBC subtypes
2005
HOX genes: not just myeloid oncogenes any more
Lawrence H, Fischbach N, Largman C. HOX genes: not just myeloid oncogenes any more. Leukemia 2005, 19: 1328-1330. PMID: 15931267, DOI: 10.1038/sj.leu.2403816.Commentaries, Editorials and Letters